Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatitis B virus (HBV) RNA consists of several distinct transcripts, including the pregenomic RNA (pgRNA) and various subgenomic mRNAs, which are transcribed from the covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes (Source: NIH, PubMed). The pgRNA serves as the essential template for reverse transcription into new viral DNA and also encodes the core and polymerase proteins, while subgenomic RNAs encode the surface antigens (HBsAg) and X protein (Source: Journal of Hepatology). These RNAs are critical for maintaining the viral lifecycle and contributing to the high levels of viral proteins that suppress the host immune response. Therapeutic strategies targeting HBV RNA, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), are designed to bind and trigger the degradation of these transcripts (Source: GSK, Vir Biotechnology). By reducing the expression of all HBV proteins, including HBsAg, these therapies aim to restore the host's immune control over the virus, potentially leading to a functional cure for chronic hepatitis B (Source: Lancet Gastroenterology & Hepatology). Furthermore, serum HBV RNA has emerged as a significant biomarker for monitoring the activity of intrahepatic cccDNA and predicting treatment response in patients undergoing antiviral therapy (Source: Hepatology International).
Degradation of viral RNA transcripts via RNA interference (siRNA) or antisense oligonucleotides (ASO) to inhibit viral protein production and replication.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatitis B virus RNA (HBV RNA) (HBV RNA).